Literature DB >> 35471500

Bringing mass spectrometry into the care of patients with multiple myeloma.

David L Murray1.   

Abstract

Serum protein electrophoresis methods are widely employed to detect, quantify and isotype M-proteins for multiple myeloma patients. Increasing clinical demands to detect residual disease and interferences from new therapeutic monoclonal antibody treatments have stretched electrophoretic methods to their analytical limits. Newer techniques to detect M-proteins using mass spectrometry (MS) are emerging with improved clinical and analytical performance. These techniques are beginning to gain traction within the routine clinical lab testing. This review describes these MS methods with attention to the current and future roles such testing could play in the care of multiple myeloma patients.
© 2022. Japanese Society of Hematology.

Entities:  

Keywords:  Electrophoresis; M-protein; MALDI-TOF; Mass spectroscopy; Minimal residual disease; Multiple myeloma; Paraprotein

Year:  2022        PMID: 35471500     DOI: 10.1007/s12185-022-03364-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  41 in total

1.  Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.

Authors:  H Robert Bergen; Surendra Dasari; Angela Dispenzieri; John R Mills; Marina Ramirez-Alvarado; Renee C Tschumper; Diane F Jelinek; David R Barnidge; David L Murray
Journal:  Clin Chem       Date:  2015-10-01       Impact factor: 8.327

Review 2.  Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins.

Authors:  M Zajec; P Langerhorst; M M VanDuijn; J Gloerich; H Russcher; A J van Gool; T M Luider; I Joosten; Y B de Rijke; J F M Jacobs
Journal:  Clin Chem       Date:  2020-03-01       Impact factor: 8.327

Review 3.  Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Maria A V Willrich; David L Murray; Robert A Kyle
Journal:  Clin Biochem       Date:  2017-05-04       Impact factor: 3.281

Review 4.  Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory.

Authors:  David Murray; David Barnidge
Journal:  Crit Rev Clin Lab Sci       Date:  2013 Jul-Oct       Impact factor: 6.250

5.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

6.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

7.  Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.

Authors:  Pieter Langerhorst; Somayya Noori; Marina Zajec; Yolanda B De Rijke; Jolein Gloerich; Alain J van Gool; Hélène Caillon; Irma Joosten; Theo M Luider; Jill Corre; Martijn M VanDuijn; Thomas Dejoie; Joannes F M Jacobs
Journal:  Clin Chem       Date:  2021-11-26       Impact factor: 8.327

8.  Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Authors:  Joaquin Martinez-Lopez; Juan J Lahuerta; François Pepin; Marcos González; Santiago Barrio; Rosa Ayala; Noemí Puig; María A Montalban; Bruno Paiva; Li Weng; Cristina Jiménez; María Sopena; Martin Moorhead; Teresa Cedena; Immaculada Rapado; María Victoria Mateos; Laura Rosiñol; Albert Oriol; María J Blanchard; Rafael Martínez; Joan Bladé; Jesús San Miguel; Malek Faham; Ramón García-Sanz
Journal:  Blood       Date:  2014-03-19       Impact factor: 22.113

9.  Screening panels for detection of monoclonal gammopathies.

Authors:  Jerry A Katzmann; Robert A Kyle; Joanne Benson; Dirk R Larson; Melissa R Snyder; John A Lust; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Clin Chem       Date:  2009-06-11       Impact factor: 8.327

10.  Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

Authors:  J Flores-Montero; L Sanoja-Flores; B Paiva; N Puig; O García-Sánchez; S Böttcher; V H J van der Velden; J-J Pérez-Morán; M-B Vidriales; R García-Sanz; C Jimenez; M González; J Martínez-López; A Corral-Mateos; G-E Grigore; R Fluxá; R Pontes; J Caetano; L Sedek; M-C Del Cañizo; J Bladé; J-J Lahuerta; C Aguilar; A Bárez; A García-Mateo; J Labrador; P Leoz; C Aguilera-Sanz; J San-Miguel; M-V Mateos; B Durie; J J M van Dongen; A Orfao
Journal:  Leukemia       Date:  2017-01-20       Impact factor: 11.528

View more
  1 in total

1.  Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma?

Authors:  Hiroyuki Takamatsu
Journal:  Int J Hematol       Date:  2022-05-11       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.